{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:43:54Z","timestamp":1792464234018,"version":"4.5.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1001\/jamaneurol.2019.1632","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T13:23:58Z","timestamp":1561469038000},"page":"1060","source":"Crossref","is-referenced-by-count":423,"title":["Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease\u2013Related \u03b2-Amyloid Status"],"prefix":"10.1001","volume":"76","author":[{"given":"Sebastian","family":"Palmqvist","sequence":"first","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"},{"name":"Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, United Kingdom"},{"name":"UK Dementia Research Institute at UCL, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Karl","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Zink","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Bittner","sequence":"additional","affiliation":[{"name":"Genentech, a Member of the Roche Group, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Eichenlaub","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH, Penzberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"},{"name":"Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi190043r1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi190043r2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi190043r3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.dadm.2015.09.001","article-title":"Revolutionizing Alzheimer\u2019s disease and clinical trials through biomarkers.","volume":"1","author":"Mattsson","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"noi190043r4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer\u2019s disease.","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"noi190043r5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jalz.2017.02.001","article-title":"2017 Alzheimer\u2019s disease facts and figures.","volume":"13","author":"Alzheimer\u2019s Association","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi190043r6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","article-title":"Forecasting the global burden of Alzheimer\u2019s disease.","volume":"3","author":"Brookmeyer","year":"2007","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi190043r7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40291-016-0241-0","article-title":"Blood biomarkers for Alzheimer\u2019s disease: much promise, cautious progress.","volume":"21","author":"Keshavan","year":"2017","journal-title":"Mol Diagn Ther"},{"issue":"4","key":"noi190043r8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3233\/JAD-150020","article-title":"Blood protein markers of neocortical amyloid-\u00df burden: a candidate study using SOMAscan technology.","volume":"46","author":"Voyle","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"noi190043r9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3233\/JAD-180025","article-title":"Association of plasma neurofilament light chain with neocortical amyloid-\u00df load and cognitive performance in cognitively normal elderly participants.","volume":"63","author":"Chatterjee","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"noi190043r10","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jalz.2016.06.001","article-title":"Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort.","volume":"12","author":"Dage","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi190043r11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3233\/JAD-161114","article-title":"Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer\u2019s disease.","volume":"58","author":"Deters","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"noi190043r12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","article-title":"Plasma amyloid \u00df 42\/40 ratios as biomarkers for amyloid \u00df cerebral deposition in cognitively normal individuals.","volume":"8","author":"Fandos","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"noi190043r13","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u00df-amyloid in Alzheimer\u2019s disease and vascular disease.","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"noi190043r14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fnagi.2017.00226","article-title":"Plasma levels of A\u00df42 and tau identified probable Alzheimer\u2019s dementia: findings in two cohorts.","volume":"9","author":"Lue","year":"2017","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"noi190043r15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease.","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"issue":"17","key":"noi190043r16","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease.","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"noi190043r17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.neulet.2017.04.027","article-title":"Plasma neurofilament light chain levels in Alzheimer\u2019s disease.","volume":"650","author":"Zhou","year":"2017","journal-title":"Neurosci Lett"},{"issue":"7","key":"noi190043r18","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"7691","key":"noi190043r19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u00df biomarkers for Alzheimer\u2019s disease.","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"8","key":"noi190043r20","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u00df concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi190043r21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","article-title":"CSF biomarker variability in the Alzheimer\u2019s Association quality control program","volume":"9","author":"Mattsson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"6","key":"noi190043r22","doi-asserted-by":"publisher","first-page":"e100784","DOI":"10.1371\/journal.pone.0100784","article-title":"Variability of CSF Alzheimer\u2019s disease biomarkers: implications for clinical practice.","volume":"9","author":"Vos","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"noi190043r23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","article-title":"Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of\u00a0\u00df-amyloid (1-42) in human cerebrospinal fluid.","volume":"12","author":"Bittner","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"11","key":"noi190043r24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u00df PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"12","key":"noi190043r25","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","article-title":"Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment.","volume":"74","author":"Janelidze","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"noi190043r26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"noi190043r27","doi-asserted-by":"publisher","first-page":"10918","DOI":"10.1038\/ncomms10918","article-title":"Increased amyloidogenic APP processing in APOE ?4-negative individuals with cerebral \u00df-amyloidosis.","volume":"7","author":"Mattsson","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"noi190043r28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-2006-956752","article-title":"Mild cognitive impairment: current research and clinical implications.","volume":"27","author":"Petersen","year":"2007","journal-title":"Semin Neurol"},{"key":"noi190043r30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.dadm.2019.02.002","article-title":"Preanalytical sample handling recommendations for Alzheimer\u2019s disease plasma biomarkers.","volume":"11","author":"R\u00f3zga","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"issue":"10","key":"noi190043r31","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u00df-amyloid 42: a cross-validation study against amyloid positron emission tomography.","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol"},{"issue":"3","key":"noi190043r32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u00df42\/A\u00df40 and A\u00df42\/A\u00df38 ratios: better diagnostic markers of Alzheimer disease.","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"Pt 9","key":"noi190043r33","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/aww160","article-title":"Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u00df in a multicentre European memory clinic study.","volume":"139","author":"Leuzy","year":"2016","journal-title":"Brain"},{"issue":"2","key":"noi190043r34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u00df42\/40 corresponds better than A\u00df42 to amyloid PET in Alzheimer\u2019s disease.","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"noi190043r35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-016-0233-7","article-title":"Unbiased estimates of cerebrospinal fluid \u00df-amyloid 1-42 cutoffs in a large memory clinic population.","volume":"9","author":"Bertens","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"noi190043r36","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","article-title":"Earliest accumulation of \u00df-amyloid occurs within the default-mode network and concurrently affects brain connectivity.","volume":"8","author":"Palmqvist","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"noi190043r37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome.","volume":"56","author":"Petersen","year":"1999","journal-title":"Arch Neurol"},{"issue":"7","key":"noi190043r38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease.","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"19","key":"noi190043r39","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"noi190043r40","article-title":"Accurate risk estimation of beta-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms.","author":"Palmqvist","year":"2018","journal-title":"Alzheimers Dement"},{"key":"noi190043r41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.12688\/f1000research","article-title":"Using Akaike\u2019s information theoretic criterion in mixed-effects modeling of pharmacokinetic data: a simulation study.","volume":"2","author":"Olofsen","year":"2013","journal-title":"F1000Res"},{"issue":"3","key":"noi190043r42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"noi190043r43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.dadm.2016.07.002","article-title":"Assessing risk for preclinical \u00df-amyloid pathology with APOE, cognitive, and demographic information.","volume":"4","author":"Insel","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"noi190043r44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3233\/JAD-143018","article-title":"Elevation of the plasma A\u00df40\/A\u00df42 ratio as a diagnostic marker of sporadic early-onset Alzheimer\u2019s disease.","volume":"48","author":"Kim","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"noi190043r45","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: relation to age, mortality, and risk.","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"noi190043r46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography.","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"10","key":"noi190043r47","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder.","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"noi190043r48","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jalz.2018.08.014","article-title":"Accurate risk estimation of \u00df-amyloid positivity to identify prodromal Alzheimer\u2019s disease: cross-validation study of practical algorithms.","volume":"15","author":"Palmqvist","year":"2019","journal-title":"Alzheimers Dement"},{"key":"noi190043r29","unstructured":"The Swedish BIOFINDER Study. http:\/\/biofinder.se\/. Accessed May 24, 2019."}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/article-pdf\/76\/9\/1060\/17885810\/jamaneurology_palmqvist_2019_oi_190043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T20:06:10Z","timestamp":1610049970000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2736342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.1632","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}